With this collaboration, I am excited to significantly improve the productivity of conducting in vitro electrophysiological experiments on neural cells.
Atlanta, GA (PRWEB) June 02, 2011
Axion BioSystems (Axion) is pleased to announce a Cooperative Research and Development Agreement (CRADA) with the National Health and Environmental Effects Research Laboratory of the Environmental Protection Agency’s (EPA) Office of Research and Development (ORD). This CRADA was established to evaluate the neurotoxic effects of chemicals using Axion’s Maestro, the first high-throughput microelectrode array (MEA) system.
Axion recently introduced the Maestro MEA system to enable high throughput investigations of complex biological systems. In order to improve experimental throughput, Axion’s system increases both the MEA well- and electrode-count by an order of magnitude over traditional systems. The company anticipates further productivity enhancements in the near term. “We are very excited about this opportunity to work with the EPA on this project,” said Tom O’Brien, Axion’s President and CEO. “It gives us the chance to showcase the first true multiwell MEA system on the market and contribute to improving the methodology for toxic substance evaluation.”
The Company will collaborate with Dr. Timothy Shafer of the Integrated Toxicology Division at the EPA in Research Triangle Park, NC. “Traditional MEAs, despite their low-throughput nature, have shown great promise for addressing the challenges identified in The National Academies Report on Toxicity Testing in the 21st Century. With this collaboration, I am excited to significantly improve the productivity of conducting in vitro electrophysiological experiments on neural cells,” said Dr. Shafer. “I have been using Axion's multiwell system for three months and look forward to accelerated progress through this joint effort.”
It is anticipated that 30-50 chemicals will be evaluated over the next three months. This will include pesticides and other compounds known to be neurotoxic, as well as some non-toxic compounds, and those for which less information regarding their neurotoxicity is available. The results will help to establish the capabilities of MEA systems for neurotoxicity screening.
About Axion Biosystems, Inc.
Axion BioSystems develops and manufactures single- and multi-well microelectrode array (MEA) systems for in vitro electrophysiology. These real-time, label-free systems actively monitor and control electroactive tissues (e.g.neural, cardiac, spinal). This functional interface is created by combining arrays of proprietary micro-scale sensors with patented electronics that continuously adapt to the cellular environment. As a result, Axion’s systems provide unprecedented, functional information at both the single-cell and network level, opening up new opportunities for toxicology and pharmacology.